AUPH · Categories · Form 4

AUPH - SEC Form 4 insider transactions

Aurinia Pharmaceuticals Inc (AUPH) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for AUPH

• 1d
  SEC Form 4 filed by Director Johnson Craig A

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 1d
  SEC Form 4 filed by Director Goetz Kathleen

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 1d
  SEC Form 4 filed by Director Nova Tina Susan

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 1d
  SEC Form 4 filed by Director Bailey Jeffrey Allen

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 20d
  Chief Legal Officer Robertson Stephen P. was granted 115,541 shares, increasing direct ownership by 23% to 621,402 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 20d
  Chief Financial Officer Hearne Michael S was granted 116,144 shares (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 20d
  Chief Operating Officer Cole Ryan was granted 116,144 shares (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 91d
  SVP, Chief Medical Officer Keenan Greg covered exercise/tax liability with 8,069 shares, decreasing direct ownership by 5% to 154,449 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 98d
  Chief Operating Officer Donley Matthew Maxwell covered exercise/tax liability with 40,761 shares and was granted 58,160 shares, increasing direct ownership by 3% to 680,299 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 98d
  EVP, General Counsel Robertson Stephen P. was granted 59,090 shares and covered exercise/tax liability with 36,525 shares, increasing direct ownership by 5% to 505,861 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 98d
  SVP, Chief Medical Officer Keenan Greg was granted 40,586 shares, increasing direct ownership by 33% to 162,518 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 98d
  Chief Financial Officer Miller Joseph M was granted 57,229 shares and covered exercise/tax liability with 37,511 shares, increasing direct ownership by 4% to 576,421 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 98d
  Chief Executive Officer Greenleaf Peter was granted 196,403 shares and covered exercise/tax liability with 100,890 shares, increasing direct ownership by 5% to 1,840,379 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 106d
  Chief Operating Officer Donley Matthew Maxwell covered exercise/tax liability with 32,901 shares, decreasing direct ownership by 5% to 662,900 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 106d
  Chief Executive Officer Greenleaf Peter covered exercise/tax liability with 100,171 shares, decreasing direct ownership by 5% to 1,744,866 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 106d
  Chief Financial Officer Miller Joseph M covered exercise/tax liability with 32,424 shares, decreasing direct ownership by 6% to 556,703 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 106d
  EVP, General Counsel Robertson Stephen P. covered exercise/tax liability with 34,638 shares, decreasing direct ownership by 7% to 483,296 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 126d
  SVP, Chief Medical Officer Keenan Greg covered exercise/tax liability with 11,552 shares, decreasing direct ownership by 9% to 121,932 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 155d
  EVP, General Counsel Robertson Stephen P. was granted 48,558 shares and covered exercise/tax liability with 40,385 shares, increasing direct ownership by 2% to 517,934 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 155d
  Chief Operating Officer Donley Matthew Maxwell was granted 54,166 shares and covered exercise/tax liability with 42,787 shares, increasing direct ownership by 2% to 695,801 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 155d
  Chief Financial Officer Miller Joseph M was granted 49,038 shares and covered exercise/tax liability with 40,161 shares, increasing direct ownership by 2% to 589,127 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 155d
  Chief Executive Officer Greenleaf Peter was granted 165,384 shares and covered exercise/tax liability with 113,169 shares, increasing direct ownership by 3% to 1,845,037 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 197d
  Director Bailey Jeffrey Allen covered exercise/tax liability with 2,716 shares, decreasing direct ownership by 11% to 22,775 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 197d
  Director Johnson Craig A covered exercise/tax liability with 6,039 shares, decreasing direct ownership by 29% to 14,592 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 308d
  Chief Medical Officer Keenan Greg sold $210,000 worth of shares (20,000 units at $10.50), decreasing direct ownership by 13% to 133,484 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 389d
  SEC Form 4 filed by Director Nova Tina Susan

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 389d
  SEC Form 4 filed by Director Johnson Craig A

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 389d
  SEC Form 4 filed by Director Goetz Kathleen

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 389d
  SEC Form 4 filed by Director Bailey Jeffrey Allen

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 459d
  Chief Medical Officer Keenan Greg sold $68,350 worth of shares (8,305 units at $8.23), decreasing direct ownership by 5% to 153,484 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 462d
  Chief Executive Officer Greenleaf Peter was granted 624,433 shares and sold $2,871,124 worth of shares (360,540 units at $7.96), increasing direct ownership by 17% to 1,788,945 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 462d
  Chief Medical Officer Keenan Greg was granted 62,583 shares and sold $97,912 worth of shares (12,239 units at $8.00), increasing direct ownership by 45% to 161,789 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 462d
  Chief Financial Officer Miller Joseph M sold $939,612 worth of shares (118,013 units at $7.96) and was granted 196,168 shares, increasing direct ownership by 16% to 577,361 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 462d
  EVP, General Counsel Robertson Stephen P. was granted 186,512 shares and sold $975,223 worth of shares (122,479 units at $7.96), increasing direct ownership by 14% to 509,276 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 462d
  Chief Operating Officer Donley Matthew Maxwell was granted 218,348 shares and sold $994,425 worth of shares (124,893 units at $7.96), increasing direct ownership by 16% to 680,465 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 561d
  Director Smith Karen L. was granted 12,135 shares, increasing direct ownership by 96% to 24,807 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 561d
  Director Leversage Jill was granted 12,135 shares, increasing direct ownership by 94% to 25,053 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 561d
  Director Johnson Craig A was granted 20,631 shares (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 561d
  Director Bailey Jeffrey Allen was granted 12,135 shares, increasing direct ownership by 91% to 25,491 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 561d
  Director Jayne David R.W. was granted 12,135 shares, increasing direct ownership by 27% to 56,499 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 574d
  Director Bailey Jeffrey Allen converted options into 17,913 shares and sold $38,416 worth of shares (4,557 units at $8.43) (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 574d
  Director Smith Karen L. converted options into 17,913 shares and sold $44,182 worth of shares (5,241 units at $8.43) (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 627d
  SEC Form 4 filed by Former Director Mackay-Dunn R. Hector

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 670d
  Chief Commercial Officer Habig Scott Michael sold $96,902 worth of shares (18,249 units at $5.31), decreasing direct ownership by 4% to 456,338 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 748d
  Balakrishnan Brinda sold $2,985 worth of shares (520 units at $5.74), decreasing direct ownership by 3% to 17,523 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 748d
  Billen Daniel sold $30,146 worth of shares (5,252 units at $5.74), decreasing direct ownership by 16% to 28,141 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 748d
  Jayne David R.W. sold $28,390 worth of shares (4,946 units at $5.74), decreasing direct ownership by 10% to 44,364 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 748d
  Leversage Jill sold $32,201 worth of shares (5,610 units at $5.74), decreasing direct ownership by 30% to 12,918 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 748d
  Mackay-Dunn R. Hector sold $32,316 worth of shares (5,630 units at $5.74), decreasing direct ownership by 23% to 18,595 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 824d
  Greenleaf Peter sold $711,094 worth of shares (126,981 units at $5.60), decreasing direct ownership by 8% to 1,522,114 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 824d
  Miller Joseph M sold $194,942 worth of shares (34,811 units at $5.60), decreasing direct ownership by 7% to 495,928 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 824d
  Donley Matthew Maxwell sold $224,064 worth of shares (40,665 units at $5.51), decreasing direct ownership by 7% to 584,072 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 824d
  Habig Scott Michael sold $99,551 worth of shares (17,777 units at $5.60), decreasing direct ownership by 4% to 474,587 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 824d
  Robertson Stephen P. sold $323,372 worth of shares (57,745 units at $5.60), decreasing direct ownership by 12% to 443,824 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 831d
  Knappertz Volker sold $30,073 worth of shares (4,930 units at $6.10), decreasing direct ownership by 2% to 319,128 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 838d
  Knappertz Volker sold $137,800 worth of shares (25,146 units at $5.48), decreasing direct ownership by 7% to 324,058 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 838d
  Habig Scott Michael was granted 195,512 shares and sold $86,951 worth of shares (15,867 units at $5.48), increasing direct ownership by 57% to 492,364 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 838d
  Donley Matthew Maxwell was granted 216,666 shares, increasing direct ownership by 53% to 624,737 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 838d
  Robertson Stephen P. was granted 194,230 shares, increasing direct ownership by 63% to 501,569 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 838d
  Miller Joseph M was granted 196,153 shares, increasing direct ownership by 59% to 530,739 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)

Other AUPH categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends